Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIa, Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Presence of SENS-401 in the Perilymph After 7 Days of Repeated Oral Administration in Adult Participants Scheduled for Cochlear Implantation

X
Trial Profile

A Phase IIa, Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Presence of SENS-401 in the Perilymph After 7 Days of Repeated Oral Administration in Adult Participants Scheduled for Cochlear Implantation

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Arazasetron (Primary)
  • Indications Hearing loss; Sensorineural hearing loss
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Sensorion
  • Most Recent Events

    • 14 Mar 2024 According to a Sensorion media release, company communicated on March 11, 2024, that a total of 28 patients have been randomized and 25 patients have been implanted with a cochlear implant, 16 in the treated arm and 9 in the control non-treated arm.
    • 11 Mar 2024 Primary endpoint (SENS-401 perilymph detection percentage [ Time Frame: Day 7 ]) has been met, according to Sensorion media release.
    • 11 Mar 2024 According to a Sensorion media release, company plans to publish the complete readout of the study in Q3 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top